Browse Articles

Discover research articles across all indexed journals

Mitigation potential of urban greening during heatwaves and stormwater events: a modeling study for Karlsruhe, Germany

Scientific Reports Rocco Pace, Theodore A. Endreny, Marco Ciolfi et al. Feb 13, 2025 DOI: 10.1038/s41598-025-89842-z

Abstract Climate change is increasing the frequency and intensity of urban heat islands and stormwater flooding. In order to mitigate these threats cities are turning toward green infrastructure to restore the hydrologic cycle in a way that increases the ecosystem services provided by trees. Strategically designed green infrastructure can mitigate runoff volume by rainfall interception through tree canopies and redirect impervious runoff into bioswales that promote infiltration. In addition, urban greens mitigate extreme heat via evapotranspiration and shading. Here we applied the i-Tree HydroPlus model to the German city of Karlsruhe and its twenty-seven districts with varying initial conditions of tree cover to analyze the potential for both runoff and heat mitigation during dry and wet periods throughout a 5-year period. After analyzing initial tree cover and drainage conditions, we used the model to simulate a green infrastructure scenario for each district with restored hydrology and tree cover at 30%. Regarding trade-offs between runoff and heat mitigation, the results confirm that dry soils before storm events lead to greater runoff reduction by 10%, and wet soils prior to heatwaves resulted in a greater evaporative cooling. Compared to current conditions, the green infrastructure scenarios resulted in decreasing the number of extreme heat hours (Heat Index > 31 °C) per year on average by 64.5%, and to reduce runoff in average by 58% across all city districts. Thus, our simulation results show that investing into a greener infrastructure, has positive impacts on microclimate and hydrology. Finally, we discuss synergies and trade-offs of the investigated management options as well as the transferability of results to other cities.

‘High anxiety moment’: Biden’s NIH chief talks Trump 2.0 and the future of US science

Nature Max Kozlov Feb 13, 2025 DOI: 10.1038/d41586-025-00238-5

How China created AI model DeepSeek and shocked the world

Nature Gemma Conroy, Smriti Mallapaty Feb 13, 2025 DOI: 10.1038/d41586-025-00259-0

Colin Renfrew obituary: archaeologist who shifted thinking on how societies evolve

Nature Cyprian Broodbank Feb 13, 2025 DOI: 10.1038/d41586-025-00220-1

C-terminal amides mark proteins for degradation via SCF–FBXO31

Nature Matthias F. Muhar, Jakob Farnung, Martina Cernakova et al. Feb 13, 2025 DOI: 10.1038/s41586-024-08475-w

Abstract During normal cellular homeostasis, unfolded and mislocalized proteins are recognized and removed, preventing the build-up of toxic byproducts 1 . When protein homeostasis is perturbed during ageing, neurodegeneration or cellular stress, proteins can accumulate several forms of chemical damage through reactive metabolites 2,3 . Such modifications have been proposed to trigger the selective removal of chemically marked proteins 3–6 ; however, identifying modifications that are sufficient to induce protein degradation has remained challenging. Here, using a semi-synthetic chemical biology approach coupled to cellular assays, we found that C-terminal amide-bearing proteins (CTAPs) are rapidly cleared from human cells. A CRISPR screen identified FBXO31 as a reader of C-terminal amides. FBXO31 is a substrate receptor for the SKP1–CUL1–F-box protein (SCF) ubiquitin ligase SCF–FBXO31, which ubiquitylates CTAPs for subsequent proteasomal degradation. A conserved binding pocket enables FBXO31 to bind to almost any C-terminal peptide bearing an amide while retaining exquisite selectivity over non-modified clients. This mechanism facilitates binding and turnover of endogenous CTAPs that are formed after oxidative stress. A dominant human mutation found in neurodevelopmental disorders reverses CTAP recognition, such that non-amidated neosubstrates are now degraded and FBXO31 becomes markedly toxic. We propose that CTAPs may represent the vanguard of a largely unexplored class of modified amino acid degrons that could provide a general strategy for selective yet broad surveillance of chemically damaged proteins.

Signs of damage that drive protein degradation

Nature Alfred Freeberg, Michael Rapé Feb 13, 2025 DOI: 10.1038/d41586-025-00082-7

NEJM at AHA — Routine Spironolactone in Acute Myocardial Infarction

New England Journal of Medicine Eric J. Rubin, Jane Leopold, Stephen Morrissey Feb 13, 2025 DOI: 10.1056/nejme2414472

Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated <i>KRAS</i> G12C

New England Journal of Medicine Feb 13, 2025 DOI: 10.1056/nejmx240006

Maternal Anti-PF4 Antibodies as Cause of Neonatal Stroke

New England Journal of Medicine Silke Häusler, Linda Schönborn, Johann Gradl et al. Feb 13, 2025 DOI: 10.1056/nejmc2413301

Microsatellite-Instability–High Metastatic Colorectal Cancer

New England Journal of Medicine Feb 13, 2025 DOI: 10.1056/nejmc2416383

Bat genomes illuminate adaptations to viral tolerance and disease resistance

Nature Ariadna E. Morales, Yue Dong, Thomas Brown et al. Feb 13, 2025 DOI: 10.1038/s41586-024-08471-0

Transcatheter Repair versus Mitral-Valve Surgery for Secondary Mitral Regurgitation

New England Journal of Medicine Feb 13, 2025 DOI: 10.1056/nejmc2416118

Colchicine in Acute Myocardial Infarction

New England Journal of Medicine Sanjit S. Jolly, Marc-André d’Entremont, Shun Fu Lee et al. Feb 13, 2025 DOI: 10.1056/nejmoa2405922

Routine Spironolactone in Acute Myocardial Infarction

New England Journal of Medicine Sanjit S. Jolly, Marc-André d’Entremont, Bertram Pitt et al. Feb 13, 2025 DOI: 10.1056/nejmoa2405923

NEJM at ESMO — Phase 3 Trial of Cabozantinib in Advanced Neuroendocrine Tumors

New England Journal of Medicine Eric J. Rubin, Oladapo O. Yeku, Stephen Morrissey Feb 13, 2025 DOI: 10.1056/nejme2411486

Transcatheter Valve Repair in Heart Failure with Moderate to Severe Mitral Regurgitation

New England Journal of Medicine Feb 13, 2025 DOI: 10.1056/nejmc2416116

Tumoral Melanosis

New England Journal of Medicine Deshan F. Sebaratnam, James P. Pham Feb 13, 2025 DOI: 10.1056/nejmicm2413467

My Mother’s Choices

New England Journal of Medicine Hannah Kirsch Feb 13, 2025 DOI: 10.1056/nejmp2410639

Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors

New England Journal of Medicine Jennifer A. Chan, Susan Geyer, Tyler Zemla et al. Feb 13, 2025 DOI: 10.1056/nejmoa2403991

Tirzepatide for Congenital Generalized Lipodystrophy

New England Journal of Medicine Svetlana Ten, Amrit Bhangoo, Christoph Buettner Feb 13, 2025 DOI: 10.1056/nejmc2413871